MRKMerck & Co.
Price
+83%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, price roughly fair, growth steady, the market undecided.
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Merck & Co. (MRK) reported revenue of $16.6B in Q2 2026 (quarter ended Jun 30, 2026), up 5.1% from the same quarter a year earlier. That came with a gross margin of 74% and net loss of $1.33B. For the full year FY2025, revenue was $65.0B (+1.3% year on year) and net income $18.3B. Its largest product in Q2 2026 was Keytruda at $4.61B, 49% of the disclosed total, well ahead of Gardasil Gardasil9 at 5.7%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Merck & Co., Inc., Rahway, N.J., USA Announces.Earnings release · press release
- May 22, 2026On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal …Other event · Form 8-K
- Apr 30, 2026Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $9.46BThe company’s own SEC segment disclosure.
- Keytruda$4.61B49%
- Gardasil Gardasil9$542.0M6%
- Winrevair$522.0M6%
- Bridion$460.0M5%
- Pro Quad MMRII Varivax$438.0M5%
- Keytruda Qlex$395.0M4%
- Other (23)$2.50B26%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
The closest names by size in the same industry